Document is current

Article History

Received: 13 May 2024

Accepted: 17 June 2024

First Online: 2 October 2024

Conflict of interest

: V. Faihs declare that she has no competing interests. J. Ring has received consultancy and lecture fees from Viatris/Mylan, Allergopharma, ALK, Sanofi, Pfizer, abbvie. K. Brockow has independently served on advisory boards for Blueprint Medicines, Advarra, Astra Zeneca, Biomarin, receives research support from ThermoFisher and lecture honoraria from Blueprint Medicines, ThermoFisher, Novartis, Bencard, ALK. K. Beyer has received honoraria independent of this work from Aimmune Therapeutics, Bencard, Danone/Nutricia, DBV, Hycor, Infectopharm, Mabylon, Meda Pharma/Mylan, Nestle, Novartis and ThermoFisher and research support from Aimmune, ALK, Danone/Nutricia, DBV Technologies, Hipp, Hycor, Infectopharm and Novartis. E. Rietschel received fees from Viatris independently of this work. S. Schnadt received a lecture fee from Viatris independently of this work. B. Stöcker received fees or support for conferences/training courses from Viatris and ALK independently of this work. R. Treudler has received honoraria, research support or conference support independent of this work from AbbVie, ALK-Abello, Almirall, CSL-Behring, LeoPharma, Novartis, Pfizer, Sanofi, Takeda, Viatris. M. Worm declares the receipt of fees or consultancy fees from the following companies: Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, DBV Technologies S.A, Aimmune Therapeutics UK Limited, Leo Pharma GmbH, AstraZenceca GmbH, ALK-Abelló Arzneimittel GmbH, Lilly Deutschland GmbH, Kymab Limited, Amgen GmbH, Abbvie Deutschland GmbH & Co. KG, Pfizer Pharma GmbH, Mylan Germany GmbH (A Viatris Company), Boehringer Ingelheim Pharma GmbH & Co. KG, GlaxoSmithKline GmbH & Co. KG, Almirall S. A., Amgen GmbH, Pfizer Deutschland GmbH, Bristol-Myers Squibb GmbH & Co. KGaA and FomF GmbH. L. Klimek has received research grants from Allergy Therapeutics/Bencard, UK/Germany; ALK-Abelló, Denmark; Allergopharma, Germany; Aimmune, USA; ASIT Biotech, Belgium; AstraZeneca, Sweden; Bionorica, Germany; BioNTech, Germany; Biomay, Austria; Boehringer Ingelheim, Germany; Circassia, USA; Chiesi, Italy; Cytos, Switzerland; Curalogic, Denmark; HAL, Netherlands; Lofarma, Italy; Menarini, Italy; Viatris/Mylan, USA; Novartis, Switzerland; Leti, Spain; ROXALL, Germany; GlaxoSmithKline (GSK), UK; Sanofi, France; Stallergenes, France; Thermofisher, USA and/or has been a speaker or consultant for the above-mentioned pharmaceutical companies. L. Klimek is currently President of the Medical Association of German Allergists (AeDA), Vice President of the European Academy of Allergy and Clinical Immunology (EAACI), Vice President of the German Academy of Allergy and Environmental Medicine and editor of Allergo Journal and Allergo Journal International.